Stockscreener 앱 받기
46.51
0.50%
0.23
Vera Therapeutics Inc 주식(VERA)의 최신 뉴스
Insider Buy: Whats the analyst consensus on Vera Therapeutics IncTake Profit & Safe Capital Investment Plans - baoquankhu1.vn
Cantor Fitzgerald reiterates Overweight rating on Vera Therapeutics stock By Investing.com - Investing.com UK
Published on: 2026-01-16 22:59:19 - baoquankhu1.vn
Vera Therapeutics, Inc. (VERA) Granted FDA Priority Review For Atacicept - Insider Monkey
Understanding the Setup: (VERA) and Scalable Risk - Stock Traders Daily
Wall Street Analysts See a 53.05% Upside in Vera Therapeutics (VERA): Can the Stock Really Move This High? - Zacks Investment Research
Vera Therapeutics, Inc. (VERA) Stock Analysis: A 62% Upside Potential Amidst Strong Buy Ratings - DirectorsTalk Interviews
Vera Therapeutics (NASDAQ:VERA) Shares Down 7.4%Here's Why - MarketBeat
Assessing Vera Therapeutics (VERA) Valuation After Strong Recent Share Price Momentum - Yahoo Finance
Short report: Vera Therapeutics bears retreat as stock rallies - MSN
Does FDA Priority Review For Atacicept Reshape The Bull Case For Vera Therapeutics (VERA)? - Yahoo Finance
Will Vera Therapeutics Inc. stock split again soonJuly 2025 News Drivers & AI Powered Trade Plan Recommendations - Улправда
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Why Vera Therapeutics (VERA) Is Down 5.8% After FDA Priority Review Acceptance For AtaciceptAnd What's Next - Sahm
What risks investors should watch in Vera Therapeutics Inc. stockCEO Change & Free Expert Verified Stock Movement Alerts - Улправда
Vera Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference - Sahm
A Look At Vera Therapeutics (VERA) Valuation After FDA Priority Review For Atacicept In IgA Nephropathy - Sahm
Is Vera Therapeutics Inc. stock gaining market share2025 Growth vs Value & AI Powered Market Entry Ideas - Улправда
Upcoming EventsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Detailed Stock Data - FinancialContent
Vera Therapeutics, Inc.'s (NASDAQ:VERA) Shift From Loss To Profit - 富途牛牛
Will Vera Therapeutics Inc. stock attract ESG investorsRisk Management & AI Powered Market Entry Ideas - ulpravda.ru
Is Vera Therapeutics Inc. stock a safe buy before earningsJuly 2025 Reactions & Community Driven Trade Alerts - ulpravda.ru
Los Angeles Daily NewsVera Therapeutics, Inc.Class A Common Stock (Nasdaq:VERA) Stock Quote - FinancialContent
Polycythemia Vera Pipeline and Drug Development in 2025: 10+ - openPR.com
Why Vera Therapeutics Stock Zoomed Higher Today - The Globe and Mail
FDA Fast-Tracks Vera's At-Home Kidney Drug - Benzinga
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review - Investing.com Nigeria
Vera Therapeutics stock rises after FDA accepts atacicept BLA with Priority Review By Investing.com - Investing.com South Africa
Vera Therapeutics shares up 3% after co receives U.S. FDA priority review for kidney disease drug - marketscreener.com
Vera Therapeutics' Atacicept Receives FDA Priority Review for Treatment of IgAN with PDUFA Date Set for July 7, 2026 - Quiver Quantitative
Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy - FinancialContent
FDA Expedites Approval of Vera’s Home-Based Kidney Medication - Bitget
Wells Fargo sees short squeeze ahead: here are three stocks to play it - CryptoRank
Vera Therapeutics, Inc. (NASDAQ:VERA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Vera started at buy by Goldman Sachs, atacicept potential cited - MSN
These Bay Area drugmakers are hurtling toward key FDA approval decisions in 2026 - The Business Journals
Vera Therapeutics Earnings Notes - Trefis
Quarterly Earnings: Will Vera Therapeutics Inc stock attract ESG investors2025 Market Trends & Accurate Technical Buy Alerts - moha.gov.vn
Stock Traders Purchase Large Volume of Vera Therapeutics Call Options (NASDAQ:VERA) - MarketBeat
Vera Therapeutics stock drops 3% today as biotech slips into year-end trading - ts2.tech
Vera Therapeutics announces $200M public offering - MSN
Entry Recap: What risks investors should watch in Vera Therapeutics Inc stockJuly 2025 Momentum & Consistent Return Investment Signals - moha.gov.vn
Vera Therapeutics price target raised to $33 from $23 at Wedbush - MSN
50,000 Shares in Vera Therapeutics, Inc. $VERA Purchased by Swedbank AB - MarketBeat
450,700 Shares in Vera Therapeutics, Inc. $VERA Acquired by Capricorn Fund Managers Ltd - MarketBeat
Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition - ts2.tech
Vera Therapeutics (NASDAQ:VERA) Sets New 1-Year HighShould You Buy? - MarketBeat
Trading Systems Reacting to (VERA) Volatility - Stock Traders Daily
4.73%
0.92%
자본화:
|
볼륨(24시간):